Novartis News | finanzen.ch

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

17.06.14	Press Release: Novartis submits application to the FDA for meningitis B vaccine candidate Bexsero(R) to help protect US adolescents and young adults (Dow Jones)
16.06.14	Press Release: Novartis Holly Springs facility -2- (Dow Jones)
16.06.14	Press Release: Novartis Holly Springs facility becomes first US pandemic-ready site licensed by the FDA to produce cell-culture influenza vaccines (Dow Jones)
10.06.14	Press Release: Novartis Foundation for Sustainable Development to work with Netherlands Leprosy Relief to help reduce leprosy transmission (Dow Jones)
03.06.14	Press Release: Pivotal Phase III data show -2- (Dow Jones)
03.06.14	Press Release: Pivotal Phase III data show polycythemia vera patients on Novartis drug Jakavi(R) achieved significant improvement in disease control (Dow Jones)
03.06.14	Press Release: Novartis study shows Zykadia(TM) -2- (Dow Jones)
02.06.14	Press Release: Novartis study shows Zykadia(TM) -2- (Dow Jones)
02.06.14	Press Release: Novartis study shows Zykadia(TM) shrank tumors in the majority of patients with ALK+ NSCLC, regardless of prior ALK treatment (Dow Jones)
02.06.14	Press Release: Novartis data at ASCO show LBH589 -2- (Dow Jones)
02.06.14	Press Release: Novartis data at ASCO show LBH589 significantly improved progression-free survival in patients with multiple myeloma (Dow Jones)
01.06.14	Press Release: Pivotal data for Novartis' -2- (Dow Jones)
01.06.14	Press Release: Pivotal data for Novartis' investigational compound LDE225 show marked tumor responses in advanced basal cell carcinoma (Dow Jones)
01.06.14	Press Release: Novartis announces the appointment of Bruno Strigini as President of Novartis Oncology (Dow Jones)
28.05.14	Press Release: World MS Day: Novartis launches -2- (Dow Jones)
23.05.14	Press Release: Novartis provides update on EU -2- (Dow Jones)
23.05.14	Press Release: Novartis provides update on EU marketing authorization application for RLX030 in acute heart failure (Dow Jones)
23.05.14	Press Release: Novartis: Alcon receives positive -2- (Dow Jones)
23.05.14	Press Release: Novartis: Alcon receives positive CHMP opinion for Simbrinza(R), a new fixed-dose combination medicine to treat patients with glaucoma (Dow Jones)
22.05.14	Press Release: Novartis presents key advances in -2- (Dow Jones)
22.05.14	Press Release: Novartis presents key advances in cancer research at ASCO and EHA from four new pivotal studies in lung, blood and skin cancers (Dow Jones)
21.05.14	Press Release: Novartis announces positive -2- (Dow Jones)
21.05.14	Press Release: Novartis announces positive results at ATS for once-daily Ultibro(R) Breezhaler(R) versus combination therapy (tiotropium plus formoterol) (Dow Jones)
19.05.14	Press Release: Novartis announces exclusive -2- (Dow Jones)
19.05.14	Press Release: Novartis announces exclusive agreement to extend leadership in ophthalmology, leveraging novel anti-PGDF therapy Fovista(R) (Dow Jones)
16.05.14	Press Release: Novartis: FDA issues Complete Response Letter for RLX030 for acute heart failure (Dow Jones)
15.05.14	Press Release: Novartis settles patent litigation on Gleevec(R) (imatinib mesylate) with Sun Pharma subsidiary (Dow Jones)
09.05.14	Press Release: Novartis data at ARVO 2014 confirm -2- (Dow Jones)
09.05.14	Press Release: Novartis data at ARVO 2014 confirm transformational real world outcomes and highlight the safety profile of Lucentis(R) (Dow Jones)
08.05.14	Press Release: More than 19,000 Novartis associates worldwide volunteer for local causes on Community Partnership Day (Dow Jones)
05.05.14	Press Release: Novartis drug Signifor(R) LAR -3- (Dow Jones)
05.05.14	Press Release: Novartis drug Signifor(R) LAR -2- (Dow Jones)
05.05.14	Press Release: Novartis drug Signifor(R) LAR shows superior efficacy in acromegaly patients not controlled on first generation somatostatin analogues (Dow Jones)
30.04.14	Press Release: Novartis announces presentation of data at AAN showing Gilenya(R) slowed the rate of brain volume loss in MS patients (Dow Jones)
30.04.14	Press Release: Novartis announces presentation of -2- (Dow Jones)
30.04.14	Press Release: Novartis once-daily Ultibro(R) -2- (Dow Jones)
30.04.14	Press Release: Novartis once-daily Ultibro(R) Breezhaler(R) showed superior efficacy versus Seretide(R)* for COPD patients in second head-to-head study (Dow Jones)
29.04.14	Press Release: Novartis gains FDA approval for -3- (Dow Jones)
29.04.14	Press Release: Novartis gains FDA approval for -2- (Dow Jones)
29.04.14	Press Release: Novartis gains FDA approval for Zykadia(TM), first therapy for patients with ALK+ NSCLC previously treated with the ALK inhibitor crizotinib (Dow Jones)
29.04.14	Press Release: CHMP recommends EU label expansion -2- (Dow Jones)
29.04.14	Press Release: CHMP recommends EU label expansion of Novartis' Gilenya and data at AAN confirm efficacy on pre-treated MS patients (Dow Jones)
25.04.14	Press Release: Novartis' INSTEAD study for -2- (Dow Jones)
25.04.14	Press Release: Novartis' INSTEAD study for Onbrez(R) Breezhaler(R) in patients with moderate COPD meets primary objective (Dow Jones)
24.04.14	Thomson Reuters ONE/Novartis: ventes solides et -6- (Dow Jones)
24.04.14	Thomson Reuters ONE/Novartis: ventes solides et -5- (Dow Jones)
24.04.14	Thomson Reuters ONE/Novartis: ventes solides et -4- (Dow Jones)
24.04.14	Thomson Reuters ONE/Novartis: ventes solides et -3- (Dow Jones)
24.04.14	Thomson Reuters ONE/Novartis: ventes solides et -2- (Dow Jones)
23.04.14	Press Release: Novartis and Anne Geddes unveil inspirational eBook featuring meningitis survivors in honor of World Meningitis Day (Dow Jones)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Part Grp Hldg	1’263.50	2.89 %	K V
Sonova Hldg	312.10	2.66 %	K V
Novartis	93.68	2.32 %	K V
Geberit	526.80	1.97 %	K V
Roche Hldg G	254.30	1.27 %	K V
Kuehne+Nagel Int	209.50	0.72 %	K V
UBS Group	28.30	0.57 %	K V
Givaudan	3’933.00	0.36 %	K V
Nestle	76.00	0.05 %	K V
Lonza Grp	521.40	-0.04 %	K V

mehr

12.07.24		Novartis- und MorphoSys-Aktien gewinnen: Novartis kurbelt Squeeze-Out bei MorphoSys an
12.03.24		MorphoSys- und Novartis-Aktien uneinig: Bundeskartellamt erlaubt MorphoSys-Übernahme durch Novartis
31.01.24		Novartis-Aktie schwach: Novartis profitiert von Sandoz-Abspaltung - Gewinnsprung
12.06.23		Novartis-Aktie im Plus: Novartis legt für Chinook Milliardensumme auf den Tisch
25.04.23		Novartis-Aktie im Plus: Novartis hebt nach gutem Jahresbeginn die Umsatzprognose an
07.12.22		MorphoSys-Aktie und Novartis-Aktie gefragt: Krebsprogramm gegen Zahlung an Novartis auslizenziert
19.07.22		Novartis-Aktie höher: Novartis bei nahezu stabilen Umsätzen mit Gewinnrückgang - Umbau soll 1,5 Milliarden US-Dollar Kosten sparen
06.05.22		Novartis-Aktie im Minus: Produktion von Krebsmitteln in Italien und USA ausgesetzt

12.07.24

Novartis- und MorphoSys-Aktien gewinnen: Novartis kurbelt Squeeze-Out bei MorphoSys an

12.03.24

MorphoSys- und Novartis-Aktien uneinig: Bundeskartellamt erlaubt MorphoSys-Übernahme durch Novartis

31.01.24

Novartis-Aktie schwach: Novartis profitiert von Sandoz-Abspaltung - Gewinnsprung

12.06.23

Novartis-Aktie im Plus: Novartis legt für Chinook Milliardensumme auf den Tisch

25.04.23

Novartis-Aktie im Plus: Novartis hebt nach gutem Jahresbeginn die Umsatzprognose an

07.12.22

MorphoSys-Aktie und Novartis-Aktie gefragt: Krebsprogramm gegen Zahlung an Novartis auslizenziert